Fda brensocatib approval status 2026?

What is brensocatib’s FDA approval status as of 2026?

Brensocatib is an FDA-approved drug for non-cystic fibrosis bronchiectasis (NCFBE) in adults with chronic lung infection and a history of exacerbations. This approval is based on clinical trial evidence showing reductions in exacerbation frequency.[1]

Is brensocatib approved for any other conditions?

Based on the FDA approval and prescribing information reflected in public FDA materials, the approved indication is limited to non-cystic fibrosis bronchiectasis in the adult population described above.[1]

If you mean other related uses (for example, cystic fibrosis, other inflammatory lung diseases, or pediatrics), those would require separate FDA approvals and may not be covered under the current label.[1]

What does the FDA label say patients must have to qualify?

The FDA indication is tied to adult patients with:
- non-cystic fibrosis bronchiectasis
- chronic lung infection
- a history of exacerbations

Those elements are reflected in the approved indication language.[1]

How to check for any new approvals or label expansions in 2026

If you want the most up-to-date status beyond the original approval, the most reliable place to verify changes is the FDA label and drug listing for brensocatib (the FDA’s “Drugs@FDA” entry and the current label version).[1]

Sources

[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217839